NCT03493464View on ClinicalTrials.gov

BR55 in Characterization of Ovarian Lesions

PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

April 15, 2021

Study Completion Date

July 31, 2021

Conditions
Ovarian Cancer
Interventions
DRUG

BR55

A novel targeted ultrasound contrast agent

Trial Locations (1)

94304

Stanford University Medical Center, Palo Alto

Sponsors
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Bracco Diagnostics, Inc

INDUSTRY